

# IL-21 conditions antigen-presenting human $\gamma\delta$ T-cells to promote IL-10 expression in naïve and memory CD4<sup>+</sup> T-cells

Christopher J. Tyler<sup>1</sup>, Inva Hoti<sup>2</sup>, Daniel D. Griffiths<sup>1</sup>, Simone M. Cuff<sup>1</sup>, Robert Andrews<sup>3</sup>, Maximilian Keisker<sup>1</sup>, Raya Ahmed<sup>1</sup>, Hinrich P. Hansen<sup>4</sup>, James O. Lindsay<sup>2,5</sup>, Andrew J. Stagg<sup>2</sup>, Bernhard Moser<sup>1,3</sup>, Neil E. McCarthy<sup>2</sup> and Matthias Eberl<sup>1,3,\*</sup>

<sup>1</sup>*Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK;*

<sup>2</sup>*Centre for Immunobiology, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom;* <sup>3</sup>*Systems Immunity Research Institute, Cardiff University, Cardiff, UK;* <sup>4</sup>*Department of Internal Medicine I, University of Cologne, Cologne, Germany;* <sup>5</sup>*Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom*

\***Correspondence:** Matthias Eberl, Division of Infection & Immunity, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom. Phone: (44) 29 206 87011; E-mail: eberlm@cf.ac.uk.

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.


This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

Direct interaction between T-cells exerts a major influence on tissue immunity and inflammation across multiple body sites including the human gut, which is highly enriched in ‘unconventional’ lymphocytes such as  $\gamma\delta$  T-cells. We previously reported that microbial activation of human  $V\gamma9/V\delta2^+$   $\gamma\delta$  T-cells in the presence of the mucosal damage-associated cytokine IL-15 confers the ability to promote epithelial barrier defence, specifically via induction of IL-22 expression in conventional  $CD4^+$  T-cells. In the current report, we assessed whether other cytokines enriched in the gut milieu also functionally influence microbe-responsive  $V\gamma9/V\delta2$  T-cells. When cultured in the presence of IL-21,  $V\gamma9/V\delta2$  T-cells acquired the ability to induce expression of the immunoregulatory cytokine IL-10 in both naïve and memory  $CD4^+$  T-cells, at levels surpassing those induced by monocytes or monocyte-derived DCs. These findings identify an unexpected influence of IL-21 on  $V\gamma9/V\delta2$  T-cell modulation of  $CD4^+$  T-cell responses. Further analyses suggested a possible role for CD30L and/or CD40L reverse signalling in mediating IL-10 induction by IL-21 conditioned  $V\gamma9/V\delta2$  T-cells. Our findings indicate that the local microenvironment exerts a profound influence on  $V\gamma9/V\delta2$  T-cell responses to microbial challenge, leading to induction of distinct functional profiles among  $CD4^+$  T-cells that may influence inflammatory events at mucosal surfaces. Targeting these novel pathways may offer therapeutic benefit in disorders such as inflammatory bowel disease.

**Keywords:** Unconventional T-cells,  $CD4^+$  T-cells, RNAseq, mucosal immunity, antigen presentation

Graphical abstract



Accepted Manuscript

## INTRODUCTION

Control of gut immune responses to the commensal microbiota is essential to maintain healthy barrier function and prevent chronic inflammation. In the rodent intestine, this process is critically dependent on various types of antigen-presenting cells (APCs) and their ability to induce the anti-inflammatory cytokine interleukin (IL)-10 [1]. As a potent suppressor of macrophage and T-cell functions, signalling via IL-10 is crucial for limiting host responses to enteric antigens [2], the absence of which results in chronic inflammation and severe tissue damage [3]. In the transforming growth factor (TGF)- $\beta$  rich environment of the intestine, IL-10 also plays a major role in stimulating activated B-cells to produce immunoglobulin A (IgA) [4], which regulates gut colonisation by diverse microbes and confers protection against intestinal pathogens [5, 6]. Better understanding of the specific cell types and mechanisms that control IL-10 levels in human blood and tissues will therefore aid the development of novel immunotherapies for both microbial infections and inflammatory diseases.

Classically, professional APC function and control of IL-10 expression in mucosal tissues have been regarded as features restricted to myeloid cells. However, select populations of innate lymphocytes and lymphoid cells can also exhibit APC activity and stimulate conventional T-cell responses [7, 8], and could therefore also be capable of modulating IL-10 expression at epithelial barrier sites. In a murine model, commensal bacteria have been shown to protect against intestinal damage by ‘colonising’ dendritic cells and eliciting expression of IL-10 and the closely related cytokine IL-22 [9]. Subsequent work identified a further requirement for antigen presentation by group 3 innate lymphoid cells (ILC3) to regulate mucosal IgA production and coating of gut bacteria [10], as well as inducing programmed death of commensal-specific T-cells [11]. Different types of

unconventional T-cells, including V $\gamma$ 9/V $\delta$ 2 T-cells, invariant natural killer T (iNKT) cells and mucosal-associated invariant T (MAIT) cells, have also been observed to shape B-cell antibody production in an APC-like fashion, including the induction of IgA [8, 12, 13]. These data strongly suggest that ‘unconventional’ APCs can fulfil roles distinct from those performed by myeloid presenting cells, and that these functions may be particularly relevant to epithelial barrier defence and control of mucosal inflammation [8, 14]. In this context, type 3 innate lymphoid cells (ILCs) from paediatric patients with inflammatory bowel disease (IBD) display reduced expression of the antigen-presenting molecule MHC II, perhaps indicating that impaired APC function of this lineage contributes to disease pathology [11]. However, ILC identity appears highly plastic in different environments, and there are major distinctions between the innate lymphocyte compartments of mice and higher primates [15]. It therefore remains unclear to what extent non-myeloid APCs can influence IL-10 expression levels in human blood and mucosal tissues.

Colonic T-cells can express MHC II in response to challenge with specific microbes, which appear to play a dominant role in shaping effector phenotypes in the intestine [14, 16]. Of particular interest in this context are human V $\gamma$ 9/V $\delta$ 2<sup>+</sup>  $\gamma\delta$  T-cells due to their unique ability to sense the microbial metabolite (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), which is produced by a large proportion of pathogenic and commensal bacteria [17], via a mechanism that involves the butyrophilin family members BTN2A1 and BTN3A1 [18, 19]. While comprising the major  $\gamma\delta$  T-cell population in human blood, V $\gamma$ 9/V $\delta$ 2 T-cell activation leads to upregulation of the gut homing receptors integrin  $\beta$ 7 and C-C chemokine receptor 9 (CCR9), and consequently these cells are found in both healthy and inflamed intestine [20, 21]. Curiously, activated V $\gamma$ 9/V $\delta$ 2 T-cells display features of professional APCs (‘ $\gamma\delta$  T-APCs’) and are capable of priming both naïve CD4<sup>+</sup> T-cells CD8<sup>+</sup> T-cells [22]. However, most research on  $\gamma\delta$  T-APCs has focused on their excellent potential to cross-

present antigens to CD8<sup>+</sup> T-cells [23], and much less is known about their role in inducing CD4<sup>+</sup> T-cell responses.

Our previous research demonstrated that upon activation in the presence of IL-2 or IL-15, microbe-responsive human V $\gamma$ 9/V $\delta$ 2 T-cells acquire potent APC functions and polarise CD4<sup>+</sup> T-cells toward expression of interferon (IFN)- $\gamma$  and IL-22, respectively (but not IL-17) [24]. In contrast,  $\gamma\delta$  T-APCs generated in the presence of the cytokine IL-21 ( $\gamma\delta_{IL-21}$  T-APCs), which is closely related to IL-2 and IL-15 and overproduced in active IBD [25], induced lower levels of CD4<sup>+</sup> T-cell proliferation and lower expression of IFN- $\gamma$  and IL-22 [24]. Rather than giving rise to T helper 1 (Th1) and Th22-like cells, here we report that  $\gamma\delta_{IL-21}$  T-APCs are instead well-equipped to induce IL-10 responses by naïve and memory CD4<sup>+</sup> T-cells, in both allogeneic and antigen-specific autologous settings. Levels of IL-10 production by  $\gamma\delta_{IL-21}$  T-APC primed CD4<sup>+</sup> T-cells readily surpassed those produced by CD4<sup>+</sup> T-cells polarised in the presence of other APC types, including both monocytes and monocyte-derived dendritic cells (DCs). These findings identify an unexpected role for IL-21 in modulating CD4<sup>+</sup> T-cell responses in microbial infections sensed by V $\gamma$ 9/V $\delta$ 2 T-cells.

## RESULTS

### **IL-21 stimulated $\gamma\delta$ T-cells induce IL-10 production in naïve and memory CD4<sup>+</sup> T-cells.**

Our previous study showed that unlike  $\gamma\delta$  T-APCs generated in the presence of IL-2 or IL-15,  $\gamma\delta_{IL-21}$  T-APCs were poor inducers of IFN- $\gamma$  and IL-22 expression in naïve CD4<sup>+</sup> T-cells [24]. This observation, together with the failure to generate any Th17 cells in such assays, prompted us to examine possible alternative outcomes of  $\gamma\delta_{IL-21}$  T-APC primed CD4<sup>+</sup> T-cell responses in more detail. Unexpectedly, these experiments demonstrated that  $\gamma\delta_{IL-21}$  T-APCs were well equipped to induce IL-10 in naïve CD4<sup>+</sup> T-cells. In mixed lymphocyte reactions with allogeneic responder cells, the ability of  $\gamma\delta_{IL-21}$  T-APCs to give rise to IL-10<sup>+</sup> CD4<sup>+</sup> T-

cells was far greater than that of any other  $\gamma\delta$  T-APC type tested, and surpassed that of lipopolysaccharide (LPS) or peptidoglycan (PGN) activated monocytes or monocyte-derived DCs (Fig.1A). The unique capacity of  $\gamma\delta_{IL-21}$  T-APCs to induce IL-10 was particularly apparent by ELISA, showing that  $\gamma\delta_{IL-21}$  T-APC polarised  $CD4^+$  T-cells secreted substantial amounts of IL-10 into the culture medium, whereas  $CD4^+$  T-cells polarised in the presence of other  $\gamma\delta$  or myeloid APCs did not (with the exception of LPS treated monocytes) (Fig.1A).

Of note, the capacity of  $\gamma\delta_{IL-21}$  T-APCs to trigger IL-10 responses was not confined to newly primed naïve  $CD4^+$  T-cells. Using allogeneic memory  $CD4^+$  T-cells as responders,  $\gamma\delta_{IL-21}$  T-APCs readily induced far greater levels of IL-10 than other  $\gamma\delta$  T-cells, monocytes or DCs, yielding up to 9% IL-10<sup>+</sup> cells among memory  $CD4^+$  T-cells (Fig.1B). Similar results were obtained in an autologous setting, using *Staphylococcus aureus* toxic shock syndrome toxin-1 (TSST-1) superantigen, which specifically acts on  $V\beta 2^+$   $CD4^+$  T-cells, or with *Mycobacterium tuberculosis* purified protein derivative (PPD), which is believed to require antigen uptake and processing (Fig.1C). These experiments identified a distinct ability of  $\gamma\delta_{IL-21}$  T-APCs to induce IL-10 responses in both autologous TSST-1 restricted naïve  $CD4^+$  T-cells, and to a lesser extent, in PPD specific memory  $CD4^+$  T-cells. Strikingly,  $\gamma\delta_{IL-21}$  T-APCs failed to induce IL-10 in  $CD8^+$  T-cells (Fig.1D), indicating a profound difference between  $\gamma\delta$  T-APC primed  $CD4^+$  and  $CD8^+$  T-cell responses. Taken together, these findings demonstrate that  $\gamma\delta_{IL-21}$  T-APCs are potent inducers of IL-10 in both naïve and memory  $CD4^+$  T-cells.

**$\gamma\delta$  T-cell induced IL-10<sup>+</sup>  $CD4^+$  T-cells are not Th2, Treg or Tfh cells.** We next attempted to further characterise the  $\gamma\delta$  T-APC induced population of IL-10<sup>+</sup>  $CD4^+$  T-cells. While superior to other  $\gamma\delta$  T-APC preparations in their ability to induce IL-10,  $\gamma\delta_{IL-21}$  T-APCs were unable to support preferential induction of IL-4 or IL-9 in naïve (Fig.1E) or memory  $CD4^+$  T-

cells (Fig.1F). In fact, the majority of the IL-10<sup>+</sup> CD4<sup>+</sup> T-cells induced did not co-express IL-4, irrespective of whether naïve or memory CD4<sup>+</sup> T-cells were used as responders (Fig.1G), thereby identifying a distinct population of IL-10<sup>+</sup> IL-4<sup>-</sup> CD4<sup>+</sup> T-cells generated in response to  $\gamma\delta_{IL-21}$  T-APCs. We were also unable to detect any differences in secretion of the Th2 cytokines IL-4, IL-5 and IL-13 (Fig.2A) or expression of the Th2 master transcription factor *GATA3* by CD4<sup>+</sup> T-cells upon stimulation by  $\gamma\delta_{IL-2}$  T-APC,  $\gamma\delta_{IL-15}$  T-APCs or  $\gamma\delta_{IL-21}$  T-APCs (Fig.2B).

$\gamma\delta_{IL-21}$  T-APCs were only modest inducers of tumour necrosis factor (TNF)- $\alpha$  (Fig.2A), in agreement with our earlier findings that  $\gamma\delta_{IL-21}$  T-APCs exhibit only a weak pro-inflammatory profile compared with other  $\gamma\delta$  T-APC types [24].  $\gamma\delta_{IL-21}$  T-APCs also failed to induce relevant levels of C-X-C chemokine ligand 13 (CXCL13), a Tfh signature molecule (Fig.2A). Finally, CD4<sup>+</sup> T-cells that had been primed by allogeneic  $\gamma\delta_{IL-21}$  T-APCs expressed comparatively low levels of *BCL6* and *FOXP3*, the master regulators of Tfh and Treg cells, respectively (Fig.2B). These findings suggest that  $\gamma\delta_{IL-21}$  T-APCs give rise to a unique population of IL-10<sup>+</sup> IL-4<sup>-</sup> CD4<sup>+</sup> T-cells that are distinct from Th1, Th2, Th9, Th17, Th22, T follicular helper (Tfh) and T regulatory (Treg) cells. We were unable to determine the extent to which these cells resemble known populations of IL-10 producing type 1 regulatory T (Tr1) or Tr1-like T-cells [26].

**$\gamma\delta$  T-cells induce polarisation of IL-10<sup>+</sup> CD4<sup>+</sup> T-cells via co-stimulatory interactions through CD80 and CD86.** We next sought to identify the IL-10 inducing signals provided by  $\gamma\delta_{IL-21}$  T-APCs. We previously observed a crucial role for co-stimulation through CD80 or CD86 in supporting proliferation and cytokine production in naïve CD4<sup>+</sup> T-cells in response to  $\gamma\delta$  T-APCs [24]. Consistent with these data, blocking either CD80 or CD86 abrogated IL-10 production in co-cultures of naïve CD4<sup>+</sup> T-cells with  $\gamma\delta_{IL-21}$  T-APCs



(Fig.3A). In contrast, neutralising antibodies against CD70, 4-1BBL, OX40L or ICOSL had no such effect on the expression of IL-10; inhibition of CD40 signalling exerted a minor influence that failed to reach statistical significance (Fig.3A). In addition, neutralising the cytokines IFN- $\gamma$ , TNF- $\alpha$ , IL-4 or IL-6 during the polarisation of naïve CD4<sup>+</sup> T-cells by  $\gamma\delta_{IL-21}$  T-APCs did not impair their ability to produce IL-10 (Fig.3B), in line with our previous observation that  $\gamma\delta_{IL-21}$  T-APCs did not secrete relevant levels of IFN- $\gamma$ , TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IL-10, IL-12p70 or IL-23 [24]. Thus, the present findings confirmed a role for CD80 and CD86 in the generation of IL-10<sup>+</sup> CD4<sup>+</sup> T-cells by  $\gamma\delta_{IL-21}$  T-APCs but failed to identify additional polarising signals that might be required for the specific induction of IL-10.

**RNAseq analysis of  $\gamma\delta_{IL-21}$  T-APCs.** We next conducted a comprehensive RNAseq analysis of  $\gamma\delta$  T-APCs generated in the presence of IL-2, IL-15 or IL-21, aiming to define the molecular mechanism underlying selective induction of IL-10 in naïve and memory CD4<sup>+</sup> T-cells. The closely related  $\gamma$ -chain cytokine IL-7 was included in this analysis as negative control, based on our earlier observation that IL-7 stimulated  $\gamma\delta$  T-cells do not express APC markers or trigger proliferation of naïve CD4<sup>+</sup> T-cells [24].

To identify IL-21 dependent candidates potentially mediating the crosstalk between  $\gamma\delta$  T-APC and CD4<sup>+</sup> T-cells, we searched the RNAseq data for genes that were differentially upregulated in the presence of IL-21 but not with IL-2 or IL-15 (Fig.4). Reassuringly, this RNAseq analysis confirmed a preferential expression of the B-cell attracting chemokine CXCL13 by  $\gamma\delta_{IL-21}$  T-APCs relative to those generated in the presence of other cytokines, evoking our earlier identification of CXCL13 as signature protein of IL-21 stimulated  $\gamma\delta$  T-cells [12, 27] (Table 1, Table 2). Besides *CXCL13*, notable transcripts enriched in the presence of IL-21 included *COL6A3* (collagen type VI alpha 3 chain), *IGFBP4* (insulin-like growth factor binding protein 4), *TNFRSF8* (TNF receptor superfamily member 8, also

known as CD30), and *TIMP1* (TIMP metalloproteinase inhibitor 1) (Table 1, Table 2). Of note, the RNAseq analysis also confirmed a reduced expression of pro-inflammatory genes by  $\gamma\delta_{IL-21}$  T-APCs as compared to  $\gamma\delta$  T-stimulated in the presence of IL-2, such as *CSF2* (GM-CSF), *LTA* (lymphotoxin- $\alpha$ ), *IFNG* (IFN- $\gamma$ ), *OSM* (oncostatin M), *CEACAM1* (CD66a), *SOCS2* (suppressor of cytokine signalling 2), and *DUSP6* (dual specificity phosphatase 6) (Table 3), in line with our previous microarray analysis [27].

**Activated  $\gamma\delta$  T-cells in human blood and intestine express CD30.** During our previous study of autologous CD4<sup>+</sup> T-cell polarisation by  $\gamma\delta$  T-APCs, we observed an important role for the TNF superfamily member CD70 in IFN- $\gamma$  induction, and for the B7 family member ICOSL in IL-22 induction, respectively [24]. Therefore, we postulated that the most promising candidate for a role in polarising IL-10 producing CD4<sup>+</sup> T-cells was CD30, a relatively poorly characterised co-stimulatory molecule related to CD27, CD40, OX40 (CD134) and 4-1BB (CD137), which is known to interact with CD30L (CD153 or TNFSF8). Flow cytometric analyses showed that resting V $\gamma$ 9/V $\delta$ 2 T-cells from healthy blood were largely negative for CD30 (Fig.5A). Exposure of PBMC to HMB-PP for 3 days had no discernible effect on CD30 expression, but addition of IL-21 to the medium led to upregulation of CD30 on V $\gamma$ 9/V $\delta$ 2 T-cells, especially on highly activated CD25<sup>hi</sup> cells (Fig.5A). As a control, CD4<sup>+</sup> T-cells in the same PBMC cultures showed only background responses to HMB-PP and IL-21 (data not shown). To our knowledge, these experiments are the first to identify CD30 as a novel activation marker for human  $\gamma\delta$  T-cells.

Given that IL-10 and IL-21 both play important roles in the gut mucosa, we next investigated expression profiles of CD30 in human colon. These experiments showed only low levels of CD30 and HLA-DR expression by resting V $\gamma$ 9/V $\delta$ 2 T-cells in human gut tissue. Cultures treated with HMB-PP alone showed marginal increases in the expression of both

CD30 and HLA-DR but addition of IL-21 had the strongest influence, and was superior to addition of IL-2 or IL-15 (Fig.5B). These experiments confirmed that CD30 is not only an activation marker for  $\gamma\delta$  T-cells in human blood but also in the intestine, and that IL-21 in particular is a potent stimulus of CD30 and HLA-DR expression on  $\gamma\delta$  T-cells in human colon.

Taken together, our data support a model in which activated human V $\gamma$ 9/V $\delta$ 2 T-cells have marked potential to prime naïve CD4<sup>+</sup> T-cells and, depending on the local cytokine milieu, can drive their differentiation into distinct functional subsets – including Th1 and Th22 cells as published earlier, or into IL-10 producing CD4<sup>+</sup> T-cells as observed in the present study (Fig.6). Unfortunately, due to lack of commercially available reagents and funding resources we were unable to conduct further studies into the potential role of CD30 in regulating IL-10 responses by CD4<sup>+</sup> T-cells. Preliminary experiments using a soluble CD30-Fc construct [28] to trigger CD30L reverse signalling in CD4<sup>+</sup> T-cells, and using anti-CD30 blocking antibodies as control, were inconsistent (data not shown).

## DISCUSSION

IL-10 is an essential regulator of immune activity throughout the human body but plays a particularly pronounced role in the intestine where host leukocytes must co-exist in close association with a rich microbial community. Our new findings show that microbe-responsive  $\gamma\delta$  T-cells can function as novel APCs capable of priming IL-10 expression in both naïve and memory subsets of conventional CD4<sup>+</sup> T-cells. Combined with our previous study, which identified a potent ability of these cells to drive colonic T-cell production of the barrier defence cytokine IL-22 [24], our research suggests that human  $\gamma\delta$  T-APCs may help restrict microbial penetration of the gut epithelium and/or restrain host responses to actively invading pathogens, depending on the prevailing cytokine environment.

IL-10 gene-deficient mice exhibit normal lymphocyte development but suffer from chronic enterocolitis owing to their inability to restrain immune responses to gut microbes [2]. Human patients with mutations in the genes encoding IL-10 receptor subunits are similarly known to develop early onset colitis, which can effectively be ‘cured’ via allogeneic haematopoietic stem cell transplantation to restore normal functioning of this regulatory circuit [3, 29]. However, while a critical role for IL-10 in controlling immune activity has long been established, the cellular sources and specific targets of this cytokine in humans are less well defined. Indeed, rather than being essential producers of IL-10, myeloid lineage cells are instead a critical target for IL-10 signalling in preventing inflammatory disease [30, 31]. IL-10 signalling in macrophages but not T-cells has also been reported to induce regulatory phenotypes that are required for the therapeutic response to anti-TNF treatment in murine colitis [32]. Other major therapies for IBD such as vedolizumab antibody blockade of the gut-homing integrin heterodimer  $\alpha_4\beta_7$  have been observed to impact innate immune cells more potently than their presumed CD4<sup>+</sup> T-cell targets, in direct correlation with clinical efficacy [33]. It is clear therefore that a more complete understanding of regulatory mechanisms in the human gut is required, in particular an appreciation of the potential for unconventional and innate lymphocyte populations to play important roles.

Our RNAseq analysis identified a range of candidates that were preferentially expressed by  $\gamma\delta$  T-cells when activated in the presence of IL-21. Out of these, CD30 (TNFRSF8) appeared to be the most promising factor potentially involved in the induction of IL-10 in CD4<sup>+</sup> T-cells, given the modulatory role of CD30 in other immunological scenarios. In mice, CD30:CD30L signalling has been identified as a critical regulator of Th17 differentiation via effects on T:T interactions and expression of IL-2 [34]. The CD30:CD30L axis has also been implicated in the activation and maintenance of IL-17A-producing  $\gamma\delta$  T-cells within the mouse gut [35] and in interactions between  $\gamma\delta$  T-cells and immature B-cells

in the mouse spleen [36]. In the absence of this signalling pathway, mice display reduced numbers of  $\gamma\delta$  T-cells in the mucosa and increased susceptibility to infection with *Listeria monocytogenes*, whereas administration of agonistic anti-CD30 antibody is sufficient to correct these defects [37]. These data suggest that CD30:CD30L signalling is an important mediator of gut  $\gamma\delta$  T-cell responses to intestinal microbes and subsequent mucosal inflammation. Accordingly, in a rodent model of disease, CD30L<sup>-/-</sup> mice appear resistant to chemical colitis due to impaired expression of multiple cytokines including IFN- $\gamma$ , IL-17A, and IL-10 [37]. Conversely, in a mouse model of psoriasis, CD30:CD30L signalling was instead found to reduce pathology by restraining Th17 responses in skin-resident  $\gamma\delta$  T-cells [38]. Together, these data indicate that therapeutic targeting of the  $\gamma\delta$  T-cell compartment of different body sites can exert potent effects on tissue inflammation and susceptibility to microbial ingress. Our hypothesis that the CD30:CD30L axis might be involved in  $\gamma\delta$  T-cell control of CD4<sup>+</sup> T-helper responses at barrier sites fits with the body of evidence that key regulators of T-T interactions are likely to include novel targets for immunotherapy in a range of different diseases, particularly those affecting epithelial barriers. In fact, colonic T-cell expression of MHC II can be induced by specific microbes, which appear to exert a dominant influence on effector phenotypes among gut lymphocytes [16].

As with other members of the TNF and TNFR superfamilies, both CD30 and CD30L are capable of initiating intracellular signalling cascades, thereby blurring the distinction between a classical 'receptor' and its 'ligand'. So-called reverse signalling through CD30L upon engaging CD30 has been observed in various biological contexts [52, 39]. Of relevance to the present study, CD30-mediated engagement of CD30L was shown to induce cytokine secretion from monocyte-derived immature DCs and promote their differentiation into mature DCs [28]. Similarly, CD30<sup>+</sup> T-cells modulate Ig class switching as well as IgG, IgA, and IgE production through CD30L expressed on B-cells [40]. A role for CD30L reverse signalling

in T-cell differentiation was demonstrated using a viral homologue vCD30 encoded by the ectromelia (mousepox) virus. In mouse models, vCD30 blocked the generation of IFN- $\gamma$  producing CD4<sup>+</sup> and CD8<sup>+</sup> T-cells *in vitro*, and inhibited Th1-driven responses against mycobacterial antigens, but did not impair Th2 inflammatory responses to helminth antigens *in vivo* [41]. Using knockout models, murine CD30L<sup>-/-</sup> T-cells were found to be defective in their ability to differentiate into Th17 cells *in vivo* and *in vitro* [34]. It has yet to be determined whether the same mechanisms operate in human CD4<sup>+</sup> T-cells, and whether IL-10 producing cell fates can be promoted by inhibition of Th1 and Th17 differentiation during priming. The role of CD30L reverse signalling during T-cell differentiation into functional subsets clearly warrants closer attention, in both human and animal models.

These considerations regarding CD30L reverse signalling evoke earlier reports of CD4<sup>+</sup> T-cell co-stimulation through the action of the related molecule CD40 (TNFRSF5) [42]. Cells expressing CD40 were actually able to trigger allogeneic CD4<sup>+</sup> T-cell responders to proliferate and favoured secretion of IL-10 [43]. CD40 is readily expressed by  $\gamma\delta$  T-APCs and is also likely to play a functional role [44]. Although it was not differentially enriched in  $\gamma\delta_{IL-21}$  T-APCs our present experiments showed a partial, albeit insignificant, inhibition of the IL-10 release by  $\gamma\delta_{IL-21}$  T-APC primed CD4<sup>+</sup> T-cells when using anti-CD40 blocking antibodies. We speculate that, similar to CD30L, reverse signalling through CD40L might contribute to polarisation of CD4<sup>+</sup> T-cells by  $\gamma\delta_{IL-21}$  T-APCs, pending further validation on a functional level.

Another noteworthy mediator identified in the present RNAseq analysis was IGFBP4, a protein that counteracts the effect of insulin-like growth factor-I (IGF-I). Counterintuitively, IGF-I itself has been shown to stimulate IL-10 production in human CD4<sup>+</sup> T-cells [45], and the action of IGF-I in driving T-cell polarisation towards a Treg phenotype

can be blocked by IGFBP4 [46]. However, there are also reports that (at least in mice) IGF-I signalling enhances the programming of pathogenic Th17 cells while suppressing genes commonly associated with Treg cells, including IL-10 [47]. As such, the IGF:IGFBP axis clearly plays a role in affecting the fate of T-cells and can regulate the balance between IL-10 producing CD4<sup>+</sup> T-cells and other effector T-cell subsets. How these observations can be reconciled with our own RNAseq analysis remains to be addressed in future work.

Taken together, the molecular pathway underlying this potent ability of  $\gamma\delta_{IL-21}$  T-APCs to induce IL-10 expression in naïve and memory CD4<sup>+</sup> T-cells remains largely unresolved, and we invite the scientific community to continue our investigations. Of note, the mechanisms postulated here may also be of relevance in tissues other than the gut. While IL-21 is overproduced in the mucosa of IBD patients, IL-21 is a signature marker of Tfh cells involved in driving the germinal centre reaction in secondary lymphoid tissues. Since both IL-10 and IL-21 induce antibody class switching towards IgA [48, 49], and IL-21 stimulated  $\gamma\delta$  T-cells promote IgA production by human B-cells [12], it is possible that IL-21 fine-tunes the outcome of  $\gamma\delta$  T-cell interactions with CD4<sup>+</sup> T-cells in the mucosa and draining lymph nodes to regulate subsequent humoral responses, in accordance with recent evidence showing that lymphatic migration of tissue-derived unconventional T-cells is a key determinant of site-specific immunity [50]. In this context, it is worth noting that patients with IgA nephropathy who are characterised by an increase in circulatory IgA antibodies with aberrant glycosylation (which form immune complexes in the kidneys that ultimately lead to glomerular damage), show a markedly different  $\gamma\delta$  T-cell repertoire in the gut compared with healthy controls [51]. Modulation of IL-21 as well as CD30, CD40 and/or IGFBP4 expression may therefore exert profound effects on immune responses in barrier tissues and systemically, hence further efforts to investigate these pathways and their immunotherapeutic



potential are clearly warranted. We are hopeful that a joint effort by researchers in the field can help solve this puzzle soon.

## **METHODS AND MATERIALS**

**Tissue samples.** Biopsies of colonic mucosa were obtained from patients undergoing colonoscopy for cancer screening or investigation of rectal bleeding but with no significant findings. Additional mucosal tissue (terminal ileum and colon) was obtained from patients undergoing surgical resection for colorectal cancer or for non-inflammatory intestinal motility disorders. Endoscopic biopsies or equivalent size pieces of resected intestinal tissue were washed in calcium and magnesium-free HBSS containing 1 mM dithiothreitol (Sigma) for 15 minutes to remove mucus and faeces, followed by incubation in 1 mM EDTA for 1 hour under constant shaking to remove the epithelium. Mucosal tissue pieces were then transferred into 24 well plates for organ cultures in complete tissue medium containing 30 U/ml IL-2 and 20 ng/ml IL-15, in the presence or absence of 10 nM HMB-PP. After 3 days, intact tissues were discarded and the egressed leukocytes seeded into 96 well round bottom plates for a further 4 days. At the end of the culture period, intestinal V $\gamma$ 9/V $\delta$ 2 T-cells and CD4<sup>+</sup> T-cells were each sorted to >99.2% purity.

**Cell isolation from blood and APC generation.** PBMC were isolated from heparinised venous blood of healthy donors or from blood bags supplied by the Welsh Blood Service (Velindre NHS Trust) using Lymphoprep (Axis-Shield). CD14<sup>+</sup> monocytes (>99% purity) were purified from PBMC using anti-CD14 microbeads (Miltenyi). Immature DCs (iDCs) were derived from monocytes over 5-6 days in the presence of 50 ng/ml GM-CSF (Miltenyi) and 50 ng/ml IL-4 (Miltenyi). Maturation of iDCs into mature DCs (mDCs) and activation of freshly isolated monocytes were achieved via stimulation for 24 hours with 100 ng/ml



*Salmonella abortus equi* LPS (Sigma), or 1 µg/ml peptidoglycan (PGN; Sigma). Vγ9<sup>+</sup> T-cells and Vδ2<sup>+</sup> T-cells (each >99% purity) were isolated using anti-TCR-Vγ9 PECy5 (Beckman Coulter) or anti-TCR-Vδ2 PE mAbs (BD Biosciences), combined with anti-PE microbeads (Miltenyi). γδ T-APCs were generated by co-culture of purified blood γδ T-cells with irradiated monocytes (50 Gy) at a 10:1 ratio, in the presence of 10 nM HMB-PP (kindly provided by Hassan Jomaa, Justus-Liebig University Giessen, Germany) with or without 100 U/ml IL-2 (Proleukin; Novartis), 20 ng/ml IL-7 (Peprotech), 20 ng/ml IL-15 (Miltenyi) or 20 ng/ml IL-21 (Zymogenetics). γδ T-APCs were cultured for 3 days and further purified either by positive selection or cell sorting to purities >99.2%. Short-term γδ T-cell stimulation assays were performed in PBMC cultures over 3 days, using 10 nM HMB-PP with or without addition of cytokines. Bulk CD4<sup>+</sup> and CD8<sup>+</sup> T-cells (each >95% purity) were isolated from PBMC via negative selection using the corresponding CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Isolation Kits, respectively (Miltenyi). For isolation of naïve and memory subsets, bulk T-cells were labelled with anti-CD4 or anti-CD8 mAbs, together with anti-CD45RA (all from BD Biosciences) and anti-CCR7 mAbs (Biolegend), and sorted using a FACS Aria II (BD Biosciences) to obtain CD45RA<sup>+</sup> CCR7<sup>+</sup> naïve and CD45RA<sup>-</sup> CCR7<sup>-</sup> memory populations, with >99.4% purity in each case as confirmed by flow cytometry.

**APC assays.** All cultures were performed using RPMI-1640 medium supplemented with 10% foetal calf serum, 50 µg/ml penicillin/streptomycin, 2 mM L-glutamine, 1% sodium pyruvate and 100 µM non-essential amino acids (Life Technologies). For mixed lymphocyte reactions, APCs and allogeneic CD4<sup>+</sup> or CD8<sup>+</sup> T-cells were co-cultured at a 1:10 ratio, as described before [24]. γδ T-APCs were irradiated at 12 Gy prior to co-culture with responder cells. For antigen-restricted responses, APCs were pulsed with 1 ng/ml TSST-1 (Toxin Technology) for 1 hour and washed three times prior to co-culture with autologous CD4<sup>+</sup> T-cells. To assess CD4<sup>+</sup> T-cell responses to complex antigen preparations, APCs were cultured

with 1 µg/ml PPD (Statens Serum Institut, Copenhagen, Denmark) for the final 24 hours of APC generation and washed three times prior to co-culture with autologous CD4<sup>+</sup> T-cells. Co-cultures were incubated for five days to assess proliferation of responder cells labelled with CFSE (Life Technologies), or for nine days prior to analysis of cytokine and transcription factor expression. For blocking of co-stimulatory molecules, APCs were pre-incubated with neutralising mAbs for 2-3 hours and washed three times, prior to addition of CD4<sup>+</sup> T-cells; for inhibition of APC derived cytokines, appropriate blocking reagents were added directly to MLR assays. Blocking reagents used were anti-ICOSL (9F.8A4; Biolegend), anti-IFN-γ (B27), anti-IL-4 (8D4-8) and anti-IL-6 (MQ2-13A5) from Biolegend; anti-4-1BBL (H41BB-M127), anti-CD80 (2D10.4) and anti-CD86 (IT2.2) from BD Biosciences; anti-OX40L (MAB10541) from R&D Systems; sTNFR p75-IgG1 fusion protein (etanercept/Enbrel; Amgen); and anti-CD30 (HeFi-1) [ref. 52]. Agonistic reagents included anti-CD3 (OKT3), anti-CD28 (CD28.2) and anti-ICOS (ISA-3) from eBioscience; soluble CD70 (sCD70) from Jannie Borst, Netherlands Cancer Institute; and sCD30-Fc [ref. 52].

**Flow cytometry.** Cells were acquired on an eight-colour FACSCanto II (BD Biosciences) and analysed with FlowJo 10.1 (TreeStar). Anti-mouse antibody reactive beads were used to set compensation (Life Technologies). Single live lymphocytes and monocytes were gated based on light scatter and side scatter characteristics, and the exclusion of fixable Aqua dead cell stain (Invitrogen), followed by gating based on fluorescence minus one controls [24]. For surface phenotyping, anti-CD4:APC-H7 (RPA-T4), anti-CD45RA:APC (HI100), anti-TCR-Vδ2:PE (B6.1) and anti-HLA-DR:APC-H7 (L243) were from BD Biosciences; anti-TCR-Vγ9:PE-Cy5 (Immu360) from Beckman Coulter; anti-CD25:APC (BC96) from eBioscience; anti-CD3:BV421 (UCHT-1) and anti-CD14:BV421 (M5E2) from Biolegend; and anti-CD30 (BerH2) from Invitrogen; together with appropriate isotype controls. For detection of intracellular cytokines, cells were restimulated with 10 ng/ml phorbol 12-

myristate 13-acetate (Sigma) and 1  $\mu$ M ionomycin (Sigma) for 5 hours, and cultures were supplemented with 10  $\mu$ g/ml brefeldin A (Sigma) during the last 4 hours of the incubation period. Intracellular cytokines were detected using anti-IFN- $\gamma$ :BV421 (4S.B3), anti-IL-9 (MH9A4) and anti-IL-10 (JES3-9D7) from Biolegend; anti-IL-17A:APC (eBio64DEC17) and anti-IL-22:PE-Cy7 (22URTI) from eBioscience); and anti-IL-4 (8D4-8) from BD Biosciences.

**ELISA.** Cell-free supernatants from resting or stimulated  $\gamma\delta$  T-cell, DC or monocyte cultures were collected after 3 day incubation. Supernatants from 50,000 polarised CD4<sup>+</sup> T-cells were collected after 24 hour incubation with 10 ng/ml PMA and 1  $\mu$ g/ml ionomycin. Supernatants from intestinal tissue cells were collected after 3 days in culture. Soluble cytokines were detected using conventional ELISA kits for IFN- $\gamma$  (Biolegend); IL-4, IL-5, IL-10, IL-13, IL-17 and IL-22 (eBioscience); and CXCL13 (R&D Systems). All samples were measured in duplicate on a Dynex MRX II reader.

**qPCR analysis of CD4<sup>+</sup> T-cells.** CD4<sup>+</sup> T-cell responders were sorted from co-cultures with irradiated APCs to purities >99.1%. Total RNA was extracted using the RNeasy Micro Kit (Qiagen), examined qualitatively and quantitatively using a NanoDrop ND1000 (Thermo Fisher Scientific), and used to generate cDNA with the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Transcripts were quantified by real-time quantitative PCR (qPCR) using the ViiA7 Real-Time PCR System (Thermo Fisher Scientific) [24]. Predesigned TaqMan Gene Expression Assays and the Taqman Universal Master Mix II (no UNG) were used according to the manufacturers' instructions: *TBX21*, Hs00203436\_m1; *GATA3*, Hs00231122\_m1; *RORC*, Hs01076112\_m1; *AHR*, Hs00169233\_m1; *FOXP3*, Hs01085834\_m1; *BCL6*, Hs00153368\_m1; and *PPIL2*, Hs00204962\_m1 (all from Thermo Fisher Scientific). All samples were measured in triplicate. Measured mRNA abundance

was normalised to *PPIL2* (cyclophilin) using the ExpressionSuite Software (Thermo Fisher Scientific), and is presented as arbitrary units (AU).

**RNAseq analysis of  $\gamma\delta$  T-cells.** Monocytes were freshly isolated and irradiated at 50 Gy prior to co-culture with freshly isolated autologous  $\gamma\delta$  T-cells at a monocyte to  $\gamma\delta$  T-cell ratio of 1:10. Cultures were treated with 10 nM HMB-PP alone, or in combination with 100 U/ml IL-2, 20 ng/ml IL-15 or 20 ng/ml IL-21. After three days in culture, CD3<sup>+</sup> V $\delta$ 2<sup>+</sup> T-cells were enriched by cell sorting using a FACS Aria II (BD Biosciences), to purities >99.8%. Total RNA was extracted from cell pellets using the RNeasy Micro Kit (Qiagen) and examined qualitatively and quantitatively using the TapeStation 2200 system (Agilent) and a Qubit fluorometer (Thermo Fisher Scientific). Ribosomal RNA was depleted as part of the Illumina Stranded Total RNA Prep protocol using coated magnetic beads; the remaining RNA was fragmented and denatured, and first and second strand cDNA synthesis and anchor ligation was carried out according to the manufacturer's instructions. Resulting libraries were quality-controlled using the TapeStation 2200 and Qubit systems, and pooled in equimolar amounts. Samples were subjected to paired-end sequencing with 75 bp reads on a NextSeq 500 sequencer (Illumina), generating >50 million reads per sample.

**Bioinformatics.** RNA sequencing data were processed taking advantage of the Nextflow nf-core RNASeq (version 3.14.0) pipeline [53, 54], using the Hisat2 aligner, and removing ribosomal reads. The Binary Alignment Map files produced from this pipeline were used as input for featureCounts (Subread package, version 2.0.1), to obtain a count table, using ENSEMBL *Homo sapiens* GRCh38 (version 108) as reference genome for alignment and feature counting [55]. The count table was then imported into R version 4.3.1 using RStudio IDE version 2023.6.1.524 (Posit Software). Differential gene expression analysis was carried out using DESeq2 (version 1.42.0), and genes with a log<sub>2</sub> fold change >2.5 and an adjusted *p*-

value  $<0.05$  were considered differentially expressed. Gene expression was visualised using EnhancedVolcano (version 1.20.0).

**Statistical analysis and data presentation.** Statistical analyses were performed using GraphPad Prism 6.0 software. Differences between groups were analysed using Kruskal-Wallis tests combined with Dunn's post-tests; matched data were analysed using Friedman tests combined with Dunn's multiple comparisons tests. In the graphs, each data point represents an individual donor; asterisks depict statistically significant differences: \*  $p<0.05$ ; \*\*  $p<0.01$ ; \*\*\*  $p<0.001$ ; \*\*\*\*  $p<0.0001$ . Horizontal lines display the mean, error bars indicate the standard deviation.

Accepted Manuscript

## ABBREVIATIONS

**APC**, antigen presenting cell

**BTN**, butyrophilin

**CCR**, C-C chemokine receptor

**CFSE**, carboxyfluorescein succinimidyl ester

**CXCL**, C-X-C chemokine ligand

**DC**, dendritic cell

**HLA-DR**, human leukocyte antigen DR isotype

**HMB-PP**, (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate

**IBD**, inflammatory bowel disease

**iDC**, immature dendritic cell

**IFN**, interferon

**IgA**, immunoglobulin A

**IGFBP4**, insulin-like growth factor binding protein 4

**IL**, interleukin

**ILC**, innate lymphoid cell

**iNKT**, invariant natural killer T

**LPS**, lipopolysaccharide

**PGN**, peptidoglycan

**PBMC**, peripheral blood mononuclear cells

**PPD**, purified protein derivative

**RNAseq**, RNA sequencing

**Tfh**, T follicular helper

**TGF- $\beta$** , transforming growth factor- $\beta$

**Th**, T helper

**TNF**, tumour necrosis factor

**TNFRSF**, TNF receptor superfamily member

**TNFSF**, TNF superfamily member

**Tr1**, type 1 T regulatory

**Treg**, T regulatory

**TSST-1**, toxic shock syndrome toxin-1

## **ACKNOWLEDGEMENTS**

We would like to thank Catherine Naseriyan for cell sorting; Angela Marchbank and Nicholas Kent for the RNA sequencing; Hassan Jomaa for HMB-PP; Donald Foster for IL-21; Jannie Borst for sCD70; Bruno Silva-Santos for blocking antibodies; and Kirsty Emery, Ian Humphreys, Michelle McCully and Susan Wong for advice and critical comments.

## **AUTHOR CONTRIBUTIONS**

Performed laboratory experiments: CJT, IH, MK, RAh, NEM. Analysed data: CJT, DDG, SMC, RAn, NEM, ME. Provided crucial reagents: HPH. Provided access to human samples: JOL, AJS, ME. Conceived and designed the study: BM, NEM, ME. Wrote the paper: NEM, ME.

## **FUNDING**

This research was supported by a Wellcome Trust ISSF Translational Seedcorn Award (to AJS, JOL, BM and ME), an MRC Career Development Award (to NEM), an MRC PhD Studentship (to CJT), a Cardiff Cancer Research Hub PhD Studentship (to DDG), and an Erasmus+ Traineeship (to MK). We would like to point out that our team failed for five years in a row to secure follow-up funding for this project to provide deeper functional insight into the proposed mechanisms. Sadly, this is the hidden unglamorous reality of scientific research, more-often-than-not, and needs to be acknowledged as such.

## **ETHICAL APPROVAL**

Recruitment of patients and healthy volunteers was conducted according to the principles expressed in the Declaration of Helsinki and approved under reference numbers 05/Q0405/71, Harrow Research Ethics Committee; 10/H0704/74, East London Research Ethics Committee 2; P/01/023, East London and City Health Authority Research Ethics Committee; and 08/WSE04/17, South East Wales Local Ethics Committee. All individuals provided written informed consent prior to inclusion in the study.

## **CONFLICT OF INTEREST**

The authors declare that there is no conflict of interest.

## **DATA AVAILABILITY**

The raw RNAseq data underlying this article are available from ArrayExpress under accession number E-MTAB-13875. All other data will be shared upon reasonable request to the corresponding author.

Accepted Manuscript



## REFERENCES

1. Liu B, Tonkonogy SL, Sartor RB. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. *Gastroenterology*. 2011 Aug;141(2):653-62, 662.e1-4. doi: 10.1053/j.gastro.2011.04.053.
2. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell*. 1993 Oct 22;75(2):263-74. doi: 10.1016/0092-8674(93)80068-p.
3. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med*. 2009 Nov 19;361(21):2033-45. doi: 10.1056/NEJMoa0907206.
4. Defrance T, Vanbervliet B, Brière F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. *J Exp Med*. 1992 Mar 1;175(3):671-82. doi: 10.1084/jem.175.3.671.
5. Catanzaro JR, Strauss JD, Bielecka A, Porto AF, Lobo FM, Urban A, Schofield WB, Palm NW. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. *Sci Rep*. 2019 Sep 19;9(1):13574. doi: 10.1038/s41598-019-49923-2..
6. Nakajima A, Vogelzang A, Maruya M, Miyajima M, Murata M, Son A, Kuwahara T, Tsuruyama T, Yamada S, Matsuura M, Nakase H, Peterson DA, Fagarasan S, Suzuki

- K. IgA regulates the composition and metabolic function of gut microbiota by promoting symbiosis between bacteria. *J Exp Med*. 2018 Aug 6;215(8):2019-2034. doi: 10.1084/jem.20180427.
7. von Burg N, Chappaz S, Baerenwaldt A, Horvath E, Bose Dasgupta S, Ashok D, Pieters J, Tacchini-Cottier F, Rolink A, Acha-Orbea H, Finke D. Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses. *Proc Natl Acad Sci U S A*. 2014 Sep 2;111(35):12835-40. doi: 10.1073/pnas.1406908111.
  8. Tyler CJ, Doherty DG, Moser B, Eberl M. Human V $\gamma$ 9/V $\delta$ 2 T cells: Innate adaptors of the immune system. *Cell Immunol*. 2015 Jul;296(1):10-21. doi: 10.1016/j.cellimm.2015.01.008.
  9. Fung TC, Bessman NJ, Hepworth MR, Kumar N, Shibata N, Kobuley D, Wang K, Ziegler CGK, Goc J, Shima T, Umesaki Y, Sartor RB, Sullivan KV, Lawley TD, Kunisawa J, Kiyono H, Sonnenberg GF. Lymphoid-Tissue-Resident Commensal Bacteria Promote Members of the IL-10 Cytokine Family to Establish Mutualism. *Immunity*. 2016 Mar 15;44(3):634-646. doi: 10.1016/j.immuni.2016.02.019.
  10. Melo-Gonzalez F, Kammoun H, Evren E, Dutton EE, Papadopoulou M, Bradford BM, Tanes C, Fardus-Reid F, Swann JR, Bittinger K, Mabbott NA, Vallance BA, Willinger T, Withers DR, Hepworth MR. Antigen-presenting ILC3 regulate T cell-dependent IgA responses to colonic mucosal bacteria. *J Exp Med*. 2019 Apr 1;216(4):728-742. doi: 10.1084/jem.20180871.
  11. Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J, Withers DR, Hugues S, Farrar MA, Reith W, Eberl G, Baldassano RN, Laufer TM, Elson CO, Sonnenberg GF. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal

selection of commensal bacteria-specific CD4<sup>+</sup> T cells. *Science*. 2015 May 29;348(6238):1031-5. doi: 10.1126/science.aaa4812.

12. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of human  $\gamma\delta$  T cells to provide B-cell help. *Eur J Immunol*. 2012 Jan;42(1):110-9. doi: 10.1002/eji.201142017.
13. Bennett MS, Trivedi S, Iyer AS, Hale JS, Leung DT. Human mucosal-associated invariant T (MAIT) cells possess capacity for B cell help. *J Leukoc Biol*. 2017 Nov;102(5):1261-1269. doi: 10.1189/jlb.4A0317-116R.
14. McCarthy NE, Eberl M. Human  $\gamma\delta$  T-Cell Control of Mucosal Immunity and Inflammation. *Front Immunol*. 2018 May 7;9:985. doi: 10.3389/fimmu.2018.00985.
15. Guia S, Narni-Mancinelli E. Helper-like Innate Lymphoid Cells in Humans and Mice. *Trends Immunol*. 2020 May;41(5):436-452. doi: 10.1016/j.it.2020.03.002.
16. Kiner E, Willie E, Vijaykumar B, Chowdhary K, Schmutz H, Chandler J, Schnell A, Thakore PI, LeGros G, Mostafavi S, Mathis D, Benoist C; Immunological Genome Project Consortium. Gut CD4<sup>+</sup> T cell phenotypes are a continuum molded by microbes, not by T<sub>H</sub> archetypes. *Nat Immunol*. 2021 Feb;22(2):216-228. doi: 10.1038/s41590-020-00836-7.
17. Vermijlen D, Gatti D, Kouzeli A, Rus T, Eberl M.  $\gamma\delta$  T cell responses: How many ligands will it take till we know? *Semin Cell Dev Biol*. 2018 Dec;84:75-86. doi: 10.1016/j.semcdb.2017.10.009.
18. Eberl M. Antigen recognition by human  $\gamma\delta$  T cells: one step closer to knowing. *Immunol Cell Biol*. 2020 May;98(5):351-354. doi: 10.1111/imcb.12334.
19. Yuan L, Ma X, Yang Y, Qu Y, Li X, Zhu X, Ma W, Duan J, Xue J, Yang H, Huang JW, Yi S, Zhang M, Cai N, Zhang L, Ding Q, Lai K, Liu C, Zhang L, Liu X, Yao Y,

- Zhou S, Li X, Shen P, Chang Q, Malwal SR, He Y, Li W, Chen C, Chen CC, Oldfield E, Guo RT, Zhang Y. Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V $\gamma$ 9V $\delta$ 2 T cells. *Nature*. 2023 Sep;621(7980):840-848. doi: 10.1038/s41586-023-06525-3.
20. McCarthy NE, Bashir Z, Vossenkämper A, Hedin CR, Giles EM, Bhattacharjee S, Brown SG, Sanders TJ, Whelan K, MacDonald TT, Lindsay JO, Stagg AJ. Proinflammatory V $\delta$ 2<sup>+</sup> T cells populate the human intestinal mucosa and enhance IFN- $\gamma$  production by colonic  $\alpha\beta$  T cells. *J Immunol*. 2013 Sep 1;191(5):2752-63. doi: 10.4049/jimmunol.1202959.
21. McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM, Wildemann M, Bashir Z, Whelan K, Sanderson I, Lindsay JO, Stagg AJ. Azathioprine therapy selectively ablates human V $\delta$ 2<sup>+</sup> T cells in Crohn's disease. *J Clin Invest*. 2015 Aug 3;125(8):3215-25. doi: 10.1172/JCI80840.
22. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. *Science*. 2005 Jul 8;309(5732):264-8. doi: 10.1126/science.1110267.
23. Brandes M, Willimann K, Bioley G, Lévy N, Eberl M, Luo M, Tampé R, Lévy F, Romero P, Moser B. Cross-presenting human gammadelta T cells induce robust CD8<sup>+</sup> alpha beta T cell responses. *Proc Natl Acad Sci U S A*. 2009 Feb 17;106(7):2307-12. doi: 10.1073/pnas.0810059106.
24. Tyler CJ, McCarthy NE, Lindsay JO, Stagg AJ, Moser B, Eberl M. Antigen-Presenting Human  $\gamma\delta$  T Cells Promote Intestinal CD4<sup>+</sup> T Cell Expression of IL-22 and Mucosal Release of Calprotectin. *J Immunol*. 2017 May 1;198(9):3417-3425. doi: 10.4049/jimmunol.1700003.

25. Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R, Tersigni R, Alessandroni L, Biancone L, Naccari GC, MacDonald TT, Pallone F. Interleukin-21 enhances T-helper cell type I signalling and interferon-gamma production in Crohn's disease. *Gastroenterology*. 2005 Mar;128(3):687-94. doi: 10.1053/j.gastro.2004.12.042.
26. White AM, Wraith DC. Tr1-Like T Cells - An Enigmatic Regulatory T Cell Lineage. *Front Immunol*. 2016 Sep 14;7:355. doi: 10.3389/fimmu.2016.00355.
27. Vermijlen D, Ellis P, Langford C, Klein A, Engel R, Willimann K, Jomaa H, Hayday AC, Eberl M. Distinct cytokine-driven responses of activated blood  $\gamma\delta$  T cells: insights into unconventional T cell pleiotropy. *J Immunol*. 2007 Apr 1;178(7):4304-14. doi: 10.4049/jimmunol.178.7.4304.
28. Simhadri VL, Hansen HP, Simhadri VR, Reiners KS, Bessler M, Engert A, von Strandmann EP. A novel role for reciprocal CD30-CD30L signalling in the cross-talk between natural killer and dendritic cells. *Biol Chem*. 2012 Jan;393(1-2):101-6. doi: 10.1515/BC-2011-213.
29. Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascanfroni ID, Redhu NS, Frei SM, Field M, Doty AL, Goldsmith JD, Bhan AK, Loizides A, Weiss B, Yerushalmi B, Yanagi T, Lui X, Quintana FJ, Muise AM, Klein C, Horwitz BH, Glover SC, Bousvaros A, Snapper SB. Interleukin 1 $\beta$  Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency. *Gastroenterology*. 2016 Dec;151(6):1100-1104. doi: 10.1053/j.gastro.2016.08.055.
30. Shouval DS, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, Mascanfroni ID, Al Adham Z, Lavoie S, Ibourk M, Nguyen DD, Samsom JN, Escher JC, Somech R, Weiss B, Beier R, Conklin LS, Ebens CL, Santos FG, Ferreira AR, Sherlock M,

- Bhan AK, Müller W, Mora JR, Quintana FJ, Klein C, Muise AM, Horwitz BH, Snapper SB. Interleukin-10 receptor signalling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. *Immunity*. 2014 May 15;40(5):706-19. doi: 10.1016/j.immuni.2014.03.011.
31. Zigmund E, Bernshtein B, Friedlander G, Walker CR, Yona S, Kim KW, Brenner O, Krauthgamer R, Varol C, Müller W, Jung S. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. *Immunity*. 2014 May 15;40(5):720-33. doi: 10.1016/j.immuni.2014.03.012.
32. Koelink PJ, Bloemendaal FM, Li B, Westera L, Vogels EWM, van Roest M, Gloudemans AK, van 't Wout AB, Korf H, Vermeire S, Te Velde AA, Ponsioen CY, D'Haens GR, Verbeek JS, Geiger TL, Wildenberg ME, van den Brink GR. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. *Gut*. 2020 Jun;69(6):1053-1063. doi: 10.1136/gutjnl-2019-318264.
33. Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. *Gut*. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023.
34. Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack ER, Yoshikai Y. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. *J Immunol*. 2010 Aug 15;185(4):2222-30. doi: 10.4049/jimmunol.1000024.
35. Sun X, Shibata K, Yamada H, Guo Y, Muta H, Podack ER, Yoshikai Y. CD30L/CD30 is critical for maintenance of IL-17A-producing  $\gamma\delta$  T cells bearing V $\gamma$ 6

in mucosa-associated tissues in mice. *Mucosal Immunol.* 2013 Nov;6(6):1191-201. doi: 10.1038/mi.2013.18.

36. Rampoldi F, Donato E, Ullrich L, Deseke M, Janssen A, Demera A, Sandrock I, Bubke A, Juergens AL, Swallow M, Sparwasser T, Falk C, Tan L, Trumpp A, Prinz I.  $\gamma\delta$  T cells license immature B cells to produce a broad range of polyreactive antibodies. *Cell Rep.* 2022 May 24;39(8):110854. doi: 10.1016/j.celrep.2022.110854.
37. Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack ER, Iwakura Y, Yoshikai Y. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. *J Immunol.* 2010 Dec 15;185(12):7671-80. doi: 10.4049/jimmunol.1002229.
38. Yue D, You Y, Zhang X, Wang B, Wang X, Qi R, Yang F, Meng X, Yoshikai Y, Wang Y, Sun X. CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by  $V\gamma 4^+$   $\gamma\delta$  T cells. *J Autoimmun.* 2019 Jul;101:70-85. doi: 10.1016/j.jaut.2019.04.009.
39. Wiley SR, Goodwin RG, Smith CA. Reverse signalling via CD30 ligand. *J Immunol.* 1996 Oct 15;157(8):3635-9.
40. Cerutti A, Schaffer A, Goodwin RG, Shah S, Zan H, Ely S, Casali P. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. *J Immunol.* 2000 Jul 15;165(2):786-94. doi: 10.4049/jimmunol.165.2.786.
41. Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. *J Exp Med.* 2002 Sep 16;196(6):829-39. doi: 10.1084/jem.20020319.

42. Cayabyab M, Phillips JH, Lanier LL. CD40 preferentially costimulates activation of CD4<sup>+</sup> T lymphocytes. *J Immunol.* 1994 Feb 15;152(4):1523-31.
43. Rogers NJ, Jackson IM, Jordan WJ, Lombardi G, Delikouras A, Lechler RI. CD40 can costimulate human memory T cells and favors IL-10 secretion. *Eur J Immunol.* 2003 Apr;33(4):1094-104. doi: 10.1002/eji.200323475.
44. Moser B, Eberl M.  $\gamma\delta$  T-APCs: a novel tool for immunotherapy? *Cell Mol Life Sci.* 2011 Jul;68(14):2443-52. doi: 10.1007/s00018-011-0706-6.
45. Kooijman R, Coppens A. Insulin-like growth factor-I stimulates IL-10 production in human T cells. *J Leukoc Biol.* 2004 Oct;76(4):862-7. doi: 10.1189/jlb.0404248.
46. Miyagawa I, Nakayamada S, Nakano K, Yamagata K, Sakata K, Yamaoka K, Tanaka Y. Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. *J Immunol.* 2017 Sep 1;199(5):1616-1625. doi: 10.4049/jimmunol.1600230.
47. DiToro D, Harbour SN, Bando JK, Benavides G, Witte S, Laufer VA, Moseley C, Singer JR, Frey B, Turner H, Bruning J, Darley-USmar V, Gao M, Conover C, Hatton RD, Frank S, Colonna M, Weaver CT. Insulin-Like Growth Factors Are Key Regulators of T Helper 17 Regulatory T Cell Balance in Autoimmunity. *Immunity.* 2020 Apr 14;52(4):650-667.e10. doi: 10.1016/j.immuni.2020.03.013.
48. Defrance T, Vanbervliet B, Brière F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. *J Exp Med.* 1992 Mar 1;175(3):671-82. doi: 10.1084/jem.175.3.671.
49. Cho H, Jaime H, de Oliveira RP, Kang B, Spolski R, Vaziri T, Myers TG, Thovarai V, Shen Z, Fox JG, Leonard WJ, Kelsall BL. Defective IgA response to atypical



intestinal commensals in IL-21 receptor deficiency reshapes immune cell homeostasis and mucosal immunity. *Mucosal Immunol.* 2019 Jan;12(1):85-96. doi: 10.1038/s41385-018-0056-x.

50. Ataide MA, Knöpper K, Cruz de Casas P, Ugur M, Eickhoff S, Zou M, Shaikh H, Trivedi A, Grafen A, Yang T, Prinz I, Ohlsen K, Gomez de Agüero M, Beilhack A, Huehn J, Gaya M, Saliba AE, Gasteiger G, Kastenmüller W. Lymphatic migration of unconventional T cells promotes site-specific immunity in distinct lymph nodes. *Immunity.* 2022 Oct 11;55(10):1813-1828.e9. doi: 10.1016/j.immuni.2022.07.019.
51. Kaminski H, Couzi L, Eberl M. Unconventional T cells and kidney disease. *Nat Rev Nephrol.* 2021 Dec;17(12):795-813. doi: 10.1038/s41581-021-00466-8.
52. Hansen HP, Engels HM, Dams M, Paes Leme AF, Pauletti BA, Simhadri VL, Dürkop H, Reiners KS, Barnert S, Engert A, Schubert R, Quondamatteo F, Hallek M, Pogge von Strandmann E. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma. *J Pathol.* 2014 Mar;232(4):405-14. doi: 10.1002/path.4306.
53. Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. *Nat Biotechnol.* 2017 Apr 11;35(4):316-319. doi: 10.1038/nbt.3820.
54. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, Garcia MU, Di Tommaso P, Nahnsen S. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol.* 2020 Mar;38(3):276-278. doi: 10.1038/s41587-020-0439-x.
55. Martin FJ, Amode MR, Aneja A, Austine-Orimoloye O, Azov AG, Barnes I, Becker A, Bennett R, Berry A, Bhai J, Bhurji SK, Bignell A, Boddu S, Branco Lins PR,

Brooks L, Ramaraju SB, Charkhchi M, Cockburn A, Da Rin Fiorretto L, Davidson C, Dodiya K, Donaldson S, El Houdaigui B, El Naboulsi T, Fatima R, Giron CG, Genez T, Ghattaoraya GS, Martinez JG, Guijarro C, Hardy M, Hollis Z, Hourlier T, Hunt T, Kay M, Kaykala V, Le T, Lemos D, Marques-Coelho D, Marugán JC, Merino GA, Mirabueno LP, Mushtaq A, Hossain SN, Ogeh DN, Sakthivel MP, Parker A, Perry M, Piližota I, Prosovetskaia I, Pérez-Silva JG, Salam AIA, Saraiva-Agostinho N, Schuilenburg H, Sheppard D, Sinha S, Sipos B, Stark W, Steed E, Sukumaran R, Sumathipala D, Suner MM, Surapaneni L, Sutinen K, Szpak M, Tricomi FF, Urbina-Gómez D, Veidenberg A, Walsh TA, Walts B, Wass E, Willhoft N, Allen J, Alvarez-Jarreta J, Chakiachvili M, Flint B, Giorgetti S, Haggerty L, Ilsley GR, Loveland JE, Moore B, Mudge JM, Tate J, Thybert D, Trevanion SJ, Winterbottom A, Frankish A, Hunt SE, Ruffier M, Cunningham F, Dyer S, Finn RD, Howe KL, Harrison PW, Yates AD, Flicek P. Ensembl 2023. *Nucleic Acids Res.* 2023 Jan 6;51(D1):D933-D941. doi: 10.1093/nar/gkac958.

Accepted Manuscript

## TABLES

**Table 1. Top 12 most differentially expressed genes enriched in IL-21 stimulated  $\gamma\delta$  T-cells compared to IL-2 stimulated  $\gamma\delta$  T-cells. Only genes with a baseMean value >50 are shown. lfcSE, standard error of the log2FoldChange; stat, Wald test statistic.**

<b>GENE_ID</b>	<b>baseMean</b>	<b>log2FoldChange</b>	<b>lfcSE</b>	<b>stat</b>	<b>p value</b>	<b>p adjusted</b>
<i>CXCL13</i>	79.9	9.68	2.41	4.02	$5.82 \times 10^{-05}$	0.00186
<i>COL6A3</i>	394.7	6.99	1.39	5.03	$4.84 \times 10^{-07}$	$3.63 \times 10^{-05}$
<i>IGFBP4</i>	106.8	5.10	1.27	4.01	$6.05 \times 10^{-05}$	0.00191
<i>JCHAIN</i>	124.2	4.50	0.79	5.71	$1.13 \times 10^{-08}$	$1.62 \times 10^{-06}$
<i>IGHG2</i>	157.7	4.27	0.61	6.95	$3.58 \times 10^{-12}$	$8.02 \times 10^{-09}$
<i>DTX1</i>	178.6	4.13	1.01	4.11	$3.96 \times 10^{-05}$	0.00139
<i>TNFRSF8</i>	419.3	3.98	1.45	2.73	0.006249	0.05747
<i>IGHA1</i>	155.5	3.88	0.76	5.09	$3.65 \times 10^{-07}$	$2.89 \times 10^{-05}$
<i>TIMP1</i>	2331.2	3.86	1.10	3.51	$4.49 \times 10^{-04}$	0.00933
<i>BCAT1</i>	1260.2	3.66	1.06	3.44	$5.76 \times 10^{-04}$	0.01128
<i>IGLL5</i>	53.5	3.65	0.72	5.08	$3.71 \times 10^{-07}$	$2.92 \times 10^{-05}$
<i>IGHM</i>	2306.6	3.64	0.89	4.09	$4.24 \times 10^{-05}$	0.00146

**Table 2. Top 12 most differentially expressed genes enriched in IL-21 stimulated  $\gamma\delta$  T-cells compared to IL-15 stimulated  $\gamma\delta$  T-cells.** Only genes with a baseMean value >50 are shown. lfcSE, standard error of the log2FoldChange; stat, Wald test statistic.

<b>GENE_ID</b>	<b>baseMean</b>	<b>log2FoldChange</b>	<b>lfcSE</b>	<b>stat</b>	<b>p value</b>	<b>p adjusted</b>
<i>CXCL13</i>	79.9	8.52	2.37	3.60	$3.23 \times 10^{-04}$	0.01806
<i>COL6A3</i>	394.7	6.92	1.40	4.94	$7.82 \times 10^{-07}$	$3.52 \times 10^{-04}$
<i>TNFRSF8</i>	419.3	4.47	1.46	3.07	0.00214	0.063764
<i>BCAT1</i>	1260.2	4.31	1.06	4.05	$5.15 \times 10^{-05}$	0.005072
<i>NAPSB</i>	397.0	3.98	0.90	4.43	$9.33 \times 10^{-06}$	0.001691
<i>JCHAIN</i>	124.2	3.98	0.79	5.03	$4.92 \times 10^{-07}$	$2.61 \times 10^{-04}$
<i>TIMP1</i>	2331.2	3.88	1.10	3.53	$4.17 \times 10^{-04}$	0.02122
<i>DTX1</i>	178.6	3.85	1.01	3.81	$1.40 \times 10^{-04}$	0.009911
<i>IGFBP4</i>	106.8	3.83	1.26	3.05	0.00231	0.06752
<i>COL5A3</i>	1882.7	3.71	1.13	3.29	$9.87 \times 10^{-04}$	0.03843
<i>IGHG2</i>	157.7	3.29	0.61	5.43	$5.70 \times 10^{-08}$	$1.21 \times 10^{-04}$
<i>IGLL5</i>	53.5	3.16	0.72	4.38	$1.18 \times 10^{-05}$	0.00190

**Table 3. Selection of pro-inflammatory signature genes expressed at lower levels in IL-21 stimulated  $\gamma\delta$  T-cells compared to IL-2 stimulated  $\gamma\delta$  T-cells.** Only genes with a baseMean value >50 are shown. lfcSE, standard error of the log2FoldChange; stat, Wald test statistic.

<b>GENE_ID</b>	<b>baseMean</b>	<b>log2FoldChange</b>	<b>lfcSE</b>	<b>stat</b>	<b>p value</b>	<b>p adjusted</b>
<i>CSF2</i>	5465.1	-4.86	0.92	-5.29	$1.25 \times 10^{-07}$	$1.16 \times 10^{-05}$
<i>SOCS2</i>	1115.3	-4.75	1.32	-3.60	$3.16 \times 10^{-04}$	0.00720
<i>LTA</i>	22069.8	-3.76	0.92	-4.10	$4.17 \times 10^{-05}$	0.00144
<i>DUSP6</i>	1042.6	-3.51	0.57	-6.18	$6.27 \times 10^{-10}$	$2.07 \times 10^{-07}$
<i>CEACAM1</i>	61.7	-3.40	1.01	-3.36	$7.91 \times 10^{-04}$	0.01379
<i>IFNG</i>	34244.7	-3.09	1.22	-2.52	0.01165	0.08594
<i>OSM</i>	358.5	-2.66	0.58	-4.60	$4.26 \times 10^{-06}$	$2.18 \times 10^{-04}$

## FIGURE LEGENDS

**Figure 1. CD4<sup>+</sup> T-cell polarisation by  $\gamma\delta$  T-APCs.** (A) Induction of IL-10 expression in naïve CD4<sup>+</sup> T-cells by allogeneic  $\gamma\delta$  T-APCs generated under different conditions, as determined by flow cytometry (top) and ELISA (bottom) upon restimulation after nine days in culture. Myeloid APC controls included immature DCs (iDC), LPS or PGN-matured DCs (mDC<sub>LPS</sub>, mDC<sub>PGN</sub>), freshly isolated monocytes (mono), and LPS or PGN stimulated monocytes (mono<sub>LPS</sub>, mono<sub>PGN</sub>). (B) Induction of IL-10 expression in memory CD4<sup>+</sup> T-cells in response to the allogeneic APC populations shown, as determined by flow cytometry upon restimulation after nine days in culture. (C) IL-10 production by superantigen-specific naïve CD4<sup>+</sup> T-cells in response to autologous APCs pulsed with TSST-1, within the V $\beta$ 2<sup>+</sup> CD4<sup>+</sup> gate (top), and by microbial antigen-specific memory CD4<sup>+</sup> T-cells in response to autologous APCs in the presence of PPD (bottom). (D) Induction of IL-10 expression in naïve CD8<sup>+</sup> T-cells in response to allogeneic APC populations, determined as above. (E) Induction of IL-4 and IL-9 expression in naïve CD4<sup>+</sup> T-cells in response to allogeneic  $\gamma\delta$  T-APCs generated under different conditions, as assessed upon restimulation after nine days in culture. The indicated populations of myeloid APCs served as controls. (F) Induction of IL-4 and IL-9 expression in memory CD4<sup>+</sup> T-cells in response to the allogeneic APC populations shown, as determined by flow cytometry upon restimulation after nine days in culture. (G) Intracellular staining of IL-10 and IL-4 in naïve (left) and memory (right) CD4<sup>+</sup> T-cells in response to allogeneic  $\gamma\delta$  T-APCs generated under different conditions. Data in A-C, E and F were analysed using Kruskal-Wallis tests combined with Dunn's multiple comparisons tests compared to w/o APC controls ( $n=5-7$ ); data in D were analysed using a Friedman test combined with Dunn's multiple comparisons tests compared to w/o APC controls ( $n=4$ ). FACS plots are representative of experiments using cells from four different donors. ND, not done.

**Figure 2. CD4<sup>+</sup> T-cell polarisation by  $\gamma\delta$  T-APCs.** (A) Cytokine secretion by polarised CD4<sup>+</sup> T-cells generated by co-culture of naïve CD4<sup>+</sup> T-cells with allogeneic  $\gamma\delta$  T-APCs or myeloid APCs, as assessed by ELISA upon restimulation after nine days in culture. (B) Transcription factor expression by naïve CD4<sup>+</sup> T-cells after polarisation by  $\gamma\delta$  T-APCs, as determined upon restimulation after nine days in culture. Expression of transcription factors was determined by RT-PCR after FACS sorting of polarised CD4<sup>+</sup> T-cells from APC co-cultures. Data in A were analysed using Kruskal-Wallis tests combined with Dunn's multiple comparisons tests compared to w/o APC controls; data in B were analysed using a Friedman test combined with Dunn's multiple comparisons tests compared to w/o APC controls ( $n=5$ ). AU, artificial units relative to naïve CD4<sup>+</sup> T-cells.

**Figure 3. Effect of neutralising agents on IL-10 induction in naïve CD4<sup>+</sup> T-cells.** Naïve CD4<sup>+</sup> T-cells were co-cultured with  $\gamma\delta_{IL-21}$  T-APCs from allogeneic donors at an APC:responder ratio of 1:10, in the absence or presence of blocking antibodies against co-stimulatory molecules (A) or neutralising agents against polarising cytokines (B). IL-10 production was determined by flow cytometry and ELISA, upon restimulation after nine days in culture. Data were analysed using Friedman tests combined with Dunn's multiple comparisons tests compared with IgG1 controls ( $n=4$ ).

**Figure 4. RNAseq analysis of IL-21 stimulated  $\gamma\delta$  T-APCs.** Enhanced volcano plots show differentially expressed genes using  $\gamma\delta$  T-APCs generated in the presence of IL-2 (A) and IL-15 as control (B). Grey, not significant; green,  $\log_2$  fold change  $>2.5$ ; blue, adjusted  $p$ -value  $<0.05$ ; red,  $\log_2$  fold change  $>2.5$  and adjusted  $p$ -value  $<0.05$ . Total variables = 15,460.

**Figure 5. CD30 expression by microbe-responsive  $\gamma\delta$  T-cells in human blood and gut.** (A) Human PBMC from a healthy donor were cultured without (top row) or together with 10 nM HMB-PP (bottom row) in the absence (left column) or presence (right column) of 20 ng/ml IL-21, and analysed by flow cytometry after three days in culture. Density plots show expression of CD25 and CD30 on single live  $V\delta 2^+$  T-cells. (B) Expression of CD30 and HLA-DR on single live  $V\delta 2^+$  T-cells amongst colonic lymphocytes cultured in medium alone or stimulated with 10 nM HMB-PP, either in the absence or presence of 20 ng/ml of the cytokines indicated, and analysed by flow cytometry after three days. Data were generated using colonic biopsies from five different individuals. Data in B were analysed using Friedman tests combined with Dunn's multiple comparisons tests compared with medium controls ( $n=5$ ).

**Figure 6. Schematic overview of the proposed mechanisms underlying CD4<sup>+</sup> T-cell polarisation toward distinct effector functions by  $\gamma\delta$  T-APCs.** The microbial metabolite HMB-PP is sensed by  $V\gamma 9/V\delta 2$  T-cells via a process that involves the T-cell receptor (TCR) as well as the butyrophilin family members BTN2A1 and BTN3A1 (not shown). Activated microbe-responsive  $V\gamma 9/V\delta 2$  T-cells express HLA-DR ("signal 1") and co-stimulatory molecules such as CD80 and CD86 ("signal 2"), and have the capacity to induce differentiation of naïve CD4<sup>+</sup> T-cells towards distinct effector functions ("signal 3"). Cytokines signalling via the common gamma chain IL-2R $\gamma$  (CD132) present during the generation of  $\gamma\delta$  T-APCs play a pivotal role in this process. Our earlier work defined a role for signalling via IFN- $\gamma$  and CD27 in the polarisation of IFN- $\gamma$  producing Th1 cells by  $\gamma\delta_{IL-2}$  T-APCs, and signalling via TNF- $\alpha$  and ICOS in the polarisation of IL-22 producing Th22 cells by  $\gamma\delta_{IL-15}$  T-APCs [ref. 24]. The present study describes the capacity of  $\gamma\delta_{IL-21}$  T-APCs to induce IL-10 producing CD4<sup>+</sup> T-cells, and proposes a role for CD30L and/or CD40L reverse signalling in mediating this effect. Our unpublished data also suggest a potential for other types of  $\gamma\delta$  T-APCs to polarise naïve CD4<sup>+</sup> T-cells towards IL-4 producing Th2-like cells (indicated by the question marks), although the underlying mechanism remains to be defined. For the sake of simplicity, interactions via CD80 and/or CD86 that are believed to play a co-stimulatory role in each polarising condition are not shown in this model.

Figure 1








Figure 3




Figure 4






Figure 5



Accepted Manuscript

